Breaking Down SG&A Expenses: AstraZeneca PLC vs MiMedx Group, Inc.

A Tale of Two Companies: AstraZeneca PLC vs MiMedx Group, Inc.

In the world of pharmaceuticals, the allocation of Selling, General, and Administrative (SG&A) expenses can reveal much about a company's strategic priorities. From 2014 to 2023, AstraZeneca PLC and MiMedx Group, Inc. have shown contrasting approaches. AstraZeneca, a global pharmaceutical giant, consistently allocated a significant portion of its budget to SG&A, peaking at nearly 19 billion in 2022. This reflects its expansive global operations and robust marketing strategies. In contrast, MiMedx Group, Inc., a smaller player, maintained a more modest SG&A budget, with a peak of just over 258 million in 2018. This disparity highlights the different scales and market strategies of these companies. Over the decade, AstraZeneca's SG&A expenses grew by approximately 35%, while MiMedx's expenses increased by about 133%, albeit from a much smaller base. These trends underscore the dynamic nature of the pharmaceutical industry.